“So Chris, in terms of our guidance, we've assumed a range of scenarios from providing the fully contracted 2024 doses during this year to providing something less than that.”

In context

“hopefully, that gives you a sense of what we're seeing, but I just would reiterate one other point. And that's -- that as we look to the long term, given both the opportunity in China, I mentioned for the 120 million remaining females as well as the potential for the male indication, outside of China, we saw double-digit growth across all regions in the quarter. So we continue to be on track, doing well and driving growth in this important vaccine. And that's why you heard Caroline in our prepared comments reiterate our confidence in the $11 billion number by 2030, even taking into account what we saw China happening - in China this quarter. So with that, maybe I'll turn it over to Caroline and she can address your guidance specific question. Caroline? Caroline Litchfield: Thank you, Rob. So Chris, in terms of our guidance, we've assumed a range of scenarios from providing the fully contracted 2024 doses during this year to providing something less than that. If I anchor to the midpoint of our guidance, we have been measured in assuming a scenario that has less than the contracted 2024 GARDASIL doses shipped to China. And even with that, we were able to raise our guidance at the midpoint by $200 million. And that's really as a result of the underlying momentum that we have in the rest of our business, including oncology, with KEYTRUDA and WELIREG. It includes in animal health with the launch of BRAVECTO in injectable, as well as the acquisition of the Elanco aqua business, and we remain confident in our outlook for WINREVAIR and the opportunities to drive patient impact and growth consistent with our high expectations. Peter Dannenbaum: Great. Thank you, Chris. Next question, please, Brad. Operator: The next question comes from Umer Raffat of”